Halozyme Therapeutics | Frais De Vente Et D'Administration



Selling And Administration Expenses Changement Date
Acadia Pharmaceuticals USD 130.08M 3.21M 2024-12
Agios Pharmaceuticals USD 51.7M 13.16M 2024-12
Alnylam Pharmaceuticals USD 295.34M 74.35M 2024-12
Amarin USD 36.9M 1.64M 2024-09
Amgen USD 1.88B 253M 2024-12
Baxter International USD 615M 16M 2024-12
Cytokinetics USD 62.34M 5.69M 2024-12
DBV Technologies USD 6.24M 1.32M 2024-09
Eli Lilly USD 2.42B 324.7M 2024-12
Halozyme Therapeutics USD 42.25M 1.01M 2024-12
Indivior 133M 11M 2024-09
Intra Cellular Therapies USD 137.73M 5.63M 2024-12
Ionis Pharmaceuticals USD 88.08M 26.44M 2024-12
MannKind USD 23.97M 56K 2024-12
Pfizer USD 4.27B 1.06B 2024-12
United Therapeutics USD 162.5M 8.4M 2024-12



Halozyme Therapeutics Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.